The Lustgarten Foundation and Cold Spring Harbor Laboratory Partner to Create World-Class Laboratory Focused Exclusively on Pancreatic Cancer Research
The Laboratory will focus exclusively on pancreatic cancer research, with initial studies centered on early detection, drug development and drug delivery.
David Tuveson, M.D., Ph.D., who serves jointly as the Foundation's director of research and CSHL professor, will direct and lead research efforts at the laboratory. Dr. Tuveson, working with The Lustgarten Foundation and the Foundation's Pancreatic Cancer Research Consortium of six, world-renowned medical institutions, will identify, prioritize and develop targeted research aimed at ultimately finding a cure for this deadly disease.
The research conducted at the laboratory will focus initially on three key aspects of pancreatic cancer:
- Developing ways to detect pancreatic cancer early - The presence of cancer in the pancreas causes changes in a person's system that may be detected in bodily fluids, such as blood or urine. These changes will be identified so that they can be used to routinely test patients for the presence of pancreatic cancer in its earliest stages.
- Identifying new targets for drug development - New pathways will be explored that could potentially uncover new therapeutic approaches for drug development to kill and eliminate pancreatic cancers.
- Using more effective approaches to deliver drugs directly to pancreatic cancers - Existing research shows that pancreatic tumors are difficult to penetrate with chemotherapy, so new methods will be developed to ensure that the chemotherapy reaches the tumor for more effective treatment.
CSHL Professor Tuveson is the deputy director of the Cold Spring Harbor Laboratory Cancer Center, and serves as director of The Lustgarten Foundation Pancreatic Cancer Research Laboratory as well as director of research for The Lustgarten Foundation. He also has an appointment at Memorial Sloan Kettering Cancer Center in New York City, where he will conduct clinical trials with patients. As a physician-scientist, he will merge his laboratory research with his clinical research, bringing new options to patients more rapidly.